PerkinElmer Launches Innovative Gas Chromatography Line.

BOSTON -- PerkinElmer, Inc. (NYSE: PKI)

--Delivers Fastest Injection-to-Injection Time in Conventional Gas Chromatography 

--Reduces Cycle Time and Significantly Increases Sample Throughput

--Comprehensive, Single Source Solution Offers Enhanced Productivity and ROI 

PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, has introduced the Clarus(R) 600 series Gas Chromatograph (GC) and Gas Chromatograph/Mass Spectrometers (GC/MS), which offer a new level of productivity and efficiency for a wide range of GC and GC/MS applications. Powered by a patent-pending oven design, the Clarus 600 GC delivers the fastest combined heat-up and cool-down rates for a conventional gas chromatograph on the market. This latest innovation in gas chromatography enables laboratories to reduce analytical cycle times, improve sample throughput, and ultimately increase their return on investment. The Clarus 600 series addresses the needs of the full spectrum of GC and GC/MS users, including environmental contract, forensics, petrochemical and chemical quality-control (QC) laboratories.

"While the GC market spans a variety of industries and applications, all share the need for faster analytical cycle times," said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. "The redesigned oven in the Clarus 600 GC minimizes injection-to-injection time, enabling any lab to shorten its cycle times without modifying methods or compromising results."

The new oven can cool from 450 to 50 degrees C in approximately two minutes, compared with other conventional GC ovens that require four to six minutes. By significantly accelerating the cool-down time, customers can dramatically increase the number of samples analyzed per day in their labs. This improved cooling capability also enables the chromatographic separation of very volatile compounds at temperatures lower than those practical on other commercially available systems today, providing broader analytical capability.

"In today's economy, improving efficiency and maximizing productivity are keys to success. We recognize that our customers face these same challenges to be successful. Our ability to combine this fast, new oven performance with additional benefits such as Programmable Pneumatic Control (PPC), which automates labor-intensive and complex steps, allows us to provide an innovative solution to meet these challenges. This is consistent with our overall strategy of providing 'best-in-class' product offerings to meet customer needs for both GC and GC/MS," Friel noted.

Clarus 600 GC

The Clarus 600 GC features a redesign of the conventional GC oven and when coupled to four other products in the PerkinElmer GC product line - the TurboMatrix(TM) Headspace/Headspace Trap Samplers, the TurboMatrix Thermal Desorbers, the Clarus 600 Mass Spectrometer and TotalChrom(R) 6.3.1 data handling - ensures a complete, integrated and tested system that is supported and serviced from one trusted vendor.

Clarus 600 GC/MS

The Clarus 600 GC/MS not only includes best-in-class oven performance and state-of-the-art electronics, but now offers a choice of three different pumps to meet the diverse performance demands and budget requirements of a range of laboratories. Improvements also include a compact footprint to maximize laboratory bench space, the PreVent suite of column flow controls for increased uptime and productivity, and industry-leading sensitivity for both electronic ionization (EI) and chemical ionization (CI).

Featured at Upcoming Trade Shows

The Clarus 600 GC and GC/MS series will be among the PerkinElmer products on display at upcoming trade shows including: National Environmental Monitoring Conference (NEMC), Aug. 28-31, 2006, Washington D.C.; JAIMA, Aug. 30-Sept. 1, 2006, Chiba, Japan; AnalyticaChina, Sept. 19-21, 2006, Shanghai, China; ScanLab 2006, Sept. 26-28, 2006, Copenhagen, Denmark; HET Instrument, Oct. 30-Nov. 3, 2006, Utrecht, Netherlands; and Analytica-Anacon, Nov. 16-18, 2006, Bangalore, India.

For more information on the Clarus 600 GC visit www.perkinelmer.com/Clarus600GC.

For more information on the Clarus 600 GC/MS visit www.perkinelmer.com/Clarus600GCMS.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.